# A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

> **NCT05205499** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Biotyx Medical (Shenzhen) Co., Ltd.** · enrollment: 1059 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

## Key facts

- **NCT ID:** NCT05205499
- **Lead sponsor:** Biotyx Medical (Shenzhen) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2024-07-01
- **Final completion:** 2028-08
- **Target enrollment:** 1059 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205499, "A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05205499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*